157 related articles for article (PubMed ID: 32551705)
1. Programmable Delivery of Immune Adjuvant to Tumor-Infiltrating Dendritic Cells for Cancer Immunotherapy.
Liu J; Li HJ; Luo YL; Chen YF; Fan YN; Du JZ; Wang J
Nano Lett; 2020 Jul; 20(7):4882-4889. PubMed ID: 32551705
[TBL] [Abstract][Full Text] [Related]
2. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
3. Small EV-based delivery of CpG ODNs for melanoma postsurgical immunotherapy.
Lu Y; Ye H; Zhao J; Wang K; Fan X; Lu Q; Cao L; Wan B; Liu F; Sun F; Chen X; He Z; Liu H; Sun J
J Control Release; 2023 Nov; 363():484-495. PubMed ID: 37778468
[TBL] [Abstract][Full Text] [Related]
4. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
Front Immunol; 2018; 9():783. PubMed ID: 29720976
[TBL] [Abstract][Full Text] [Related]
5. Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes.
Jing Z; Li Y; Song J; Zang X
Int J Biol Macromol; 2023 Dec; 253(Pt 3):126912. PubMed ID: 37722648
[TBL] [Abstract][Full Text] [Related]
6. Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector.
Chen H; Fan Y; Hao X; Yang C; Peng Y; Guo R; Shi X; Cao X
J Mater Chem B; 2020 Jun; 8(23):5052-5063. PubMed ID: 32400816
[TBL] [Abstract][Full Text] [Related]
7. Aminated yeast β-D-glucan for macrophage-targeted delivery of CpG oligodeoxynucleotides and synergistically enhanced cancer immunotherapy.
Zhang H; Wang Z; Wang S; Zhang J; Qiu L; Chen J
Int J Biol Macromol; 2023 Dec; 253(Pt 3):126998. PubMed ID: 37729981
[TBL] [Abstract][Full Text] [Related]
8. Glycogen for lysosome-targeted CpG ODNs delivery and enhanced cancer immunotherapy.
Zhang H; Lai L; Wang Z; Zhang J; Zhou J; Nie Y; Chen J
Int J Biol Macromol; 2024 Feb; 257(Pt 1):128536. PubMed ID: 38061522
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection.
Huang Z; Gan J; Long Z; Guo G; Shi X; Wang C; Zang Y; Ding Z; Chen J; Zhang J; Dong L
Biomaterials; 2016 Jun; 90():72-84. PubMed ID: 26994345
[TBL] [Abstract][Full Text] [Related]
10. An Adjuvant Micelle-Based Multifunctional Nanosystem for Tumor Immunotherapy by Remodeling Three Types of Immunosuppressive Cells.
Meng S; Du H; Li X; Zheng X; Zhao P; Yuan Z; Huang S; Zhao Y; Dai L
ACS Nano; 2024 Jan; 18(4):3134-3150. PubMed ID: 38236616
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
Yu C; An M; Li M; Liu H
Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
[TBL] [Abstract][Full Text] [Related]
12. A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy.
Zhang R; Tang L; Wang Y; Tian Y; Wu S; Zhou B; Dong C; Zhao B; Yang Y; Xie D; Yang L
Adv Sci (Weinh); 2023 May; 10(15):e2300116. PubMed ID: 36950751
[TBL] [Abstract][Full Text] [Related]
13. CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy.
Xu L; Wang C; Zhou Y; Ren T; Wen Z
Immunol Lett; 2012 Feb; 142(1-2):55-63. PubMed ID: 22249078
[TBL] [Abstract][Full Text] [Related]
14. Regulating the surface topography of CpG nanoadjuvants
Zhang L; Zhang L; Wang Y; Jiang K; Gao C; Zhang P; Xie Y; Wang B; Zhao Y; Xiao H; Song J
Nanoscale Adv; 2023 Sep; 5(18):4758-4769. PubMed ID: 37705793
[TBL] [Abstract][Full Text] [Related]
15. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
16. Yeast β-D-glucan functionalized graphene oxide for macrophage-targeted delivery of CpG oligodeoxynucleotides and synergistically enhanced antitumor immunity.
Cheng T; Yan T; Wu J; Wang Q; Zhang H
Int J Biol Macromol; 2023 Apr; 234():123432. PubMed ID: 36716835
[TBL] [Abstract][Full Text] [Related]
17. Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy.
Zhang Y; Ma S; Liu X; Xu Y; Zhao J; Si X; Li H; Huang Z; Wang Z; Tang Z; Song W; Chen X
Adv Mater; 2021 Feb; 33(7):e2007293. PubMed ID: 33448050
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
19. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
[TBL] [Abstract][Full Text] [Related]
20. A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy.
Wang Z; Zhang Y; Liu Z; Dong K; Liu C; Ran X; Pu F; Ju E; Ren J; Qu X
Nanoscale; 2017 Sep; 9(37):14236-14247. PubMed ID: 28914317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
